Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;17(1):57-63.
doi: 10.1038/pcan.2013.46. Epub 2013 Nov 5.

Very-high-risk localized prostate cancer: definition and outcomes

Affiliations

Very-high-risk localized prostate cancer: definition and outcomes

D Sundi et al. Prostate Cancer Prostatic Dis. 2014 Mar.

Abstract

Background: Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially-some will have excellent cancer-specific survival, whereas others will experience early metastasis even after aggressive local treatments. Current nomograms, which yield continuous risk probabilities, do not separate high-risk PCa into distinct sub-strata. Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy.

Methods: We queried the Johns Hopkins radical prostatectomy database to identify 753 men with NCCN high-risk localized PCa (Gleason sum 8-10, PSA >20 ng ml(-1), or clinical stage ≥T3). Twenty-eight alternate permutations of adverse grade, stage and cancer volume were compared by their hazard ratios for metastasis and cancer-specific mortality. VHR criteria with top-ranking hazard ratios were further evaluated by multivariable analyses and inclusion of a clinically meaningful proportion of the high-risk cohort.

Results: The VHR cohort was best defined by primary pattern 5 present on biopsy, or ≥5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. These criteria encompassed 15.1% of the NCCN high-risk cohort. Compared with other high-risk men, VHR men were at significantly higher risk for metastasis (hazard ratio 2.75) and cancer-specific mortality (hazard ratio 3.44) (P<0.001 for both). Among high-risk men, VHR men also had significantly worse 10-year metastasis-free survival (37% vs 78%) and cancer-specific survival (62% vs 90%).

Conclusions: Men who meet VHR criteria form a subgroup within the current NCCN high-risk classification who have particularly poor oncological outcomes. Use of these characteristics to distinguish VHR localized PCa may help in counseling and selection optimal candidates for multimodal treatments or clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

None

Figures

Figure 1
Figure 1
Kaplan-Meier freedom from biochemical recurrence (BFS), metastasis (MFS), cancer death (CSS), and all-cause mortality (OS) stratified by very-high-risk classification

Comment in

Similar articles

Cited by

References

    1. D’Amicoa V, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick Ga, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969–74. - PubMed
    1. NCCN. Clinical practice guidelines in oncology: prostate cancer. National comprehensive cancer network. 2012 Version 3. Available from: NCCN.org. - PubMed
    1. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE) The Journal of urology. 2005 May;173(5):1557–61. - PubMed
    1. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. Elsevier Inc. 2010 Sep;76(3):710–4. - PMC - PubMed
    1. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990–2007. World journal of urology. 2008 Jun;26(3):211–8. - PMC - PubMed

Publication types

Substances